These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 26755918)
1. Modeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal care. Yun JW; Ahn JB; Kang BC Lab Anim Res; 2015 Dec; 31(4):155-65. PubMed ID: 26755918 [TBL] [Abstract][Full Text] [Related]
2. Marmoset monkey models of Parkinson's disease: which model, when and why? Eslamboli A Brain Res Bull; 2005 Dec; 68(3):140-9. PubMed ID: 16325013 [TBL] [Abstract][Full Text] [Related]
3. PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease. Ando K; Obayashi S; Nagai Y; Oh-Nishi A; Minamimoto T; Higuchi M; Inoue T; Itoh T; Suhara T PLoS One; 2012; 7(10):e46371. PubMed ID: 23056291 [TBL] [Abstract][Full Text] [Related]
4. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy. Yun JW; Ahn JB; Kwon E; Ahn JH; Park HW; Heo H; Park JS; Kim H; Paek SH; Kang BC Tissue Eng Regen Med; 2016 Feb; 13(1):100-109. PubMed ID: 30603390 [TBL] [Abstract][Full Text] [Related]
5. Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model. Hikishima K; Ando K; Komaki Y; Kawai K; Yano R; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H Neuroscience; 2015 Aug; 300():585-92. PubMed ID: 26012491 [TBL] [Abstract][Full Text] [Related]
6. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model. Ando K; Inoue T; Itoh T Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794 [TBL] [Abstract][Full Text] [Related]
7. Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus). Phillips KA; Ross CN; Spross J; Cheng CJ; Izquierdo A; Biju KC; Chen C; Li S; Tardif SD Behav Brain Res; 2017 May; 325(Pt A):51-62. PubMed ID: 28219749 [TBL] [Abstract][Full Text] [Related]
8. Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease. Verhave PS; Vanwersch RA; van Helden HP; Smit AB; Philippens IH Behav Brain Res; 2009 Jun; 200(1):214-9. PubMed ID: 19378465 [TBL] [Abstract][Full Text] [Related]
9. Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease. Choudhury GR; Daadi MM PLoS One; 2018; 13(8):e0202770. PubMed ID: 30138454 [TBL] [Abstract][Full Text] [Related]
10. The common marmoset as a novel animal model system for biomedical and neuroscience research applications. Okano H; Hikishima K; Iriki A; Sasaki E Semin Fetal Neonatal Med; 2012 Dec; 17(6):336-40. PubMed ID: 22871417 [TBL] [Abstract][Full Text] [Related]
11. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23. Willis GL; Robertson AD Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376 [TBL] [Abstract][Full Text] [Related]
12. [Application of the common marmoset to pharmacological studies]. Nomoto M Nihon Yakurigaku Zasshi; 1995 Jul; 106(1):11-8. PubMed ID: 7590519 [TBL] [Abstract][Full Text] [Related]
13. Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Hikishima K; Ando K; Yano R; Kawai K; Komaki Y; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H Radiology; 2015 May; 275(2):430-7. PubMed ID: 25602507 [TBL] [Abstract][Full Text] [Related]
14. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869 [TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Waters CM; Hunt SP; Jenner P; Marsden CD Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993 [TBL] [Abstract][Full Text] [Related]
16. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992 [TBL] [Abstract][Full Text] [Related]
17. Common marmoset (Callithrix jacchus) as a primate model for behavioral neuroscience studies. Prins NW; Pohlmeyer EA; Debnath S; Mylavarapu R; Geng S; Sanchez JC; Rothen D; Prasad A J Neurosci Methods; 2017 Jun; 284():35-46. PubMed ID: 28400103 [TBL] [Abstract][Full Text] [Related]
18. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus). Uehara S; Uno Y; Inoue T; Murayama N; Shimizu M; Sasaki E; Yamazaki H Drug Metab Dispos; 2015 May; 43(5):735-42. PubMed ID: 25735838 [TBL] [Abstract][Full Text] [Related]
19. Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T. Heo H; Ahn JB; Lee HH; Kwon E; Yun JW; Kim H; Kang BC NMR Biomed; 2017 Feb; 30(2):. PubMed ID: 28028868 [TBL] [Abstract][Full Text] [Related]
20. The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results. Beaudry F; Huot P J Neural Transm (Vienna); 2020 Oct; 127(10):1343-1358. PubMed ID: 32860561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]